Subscribe To

Price Alert Latest News Economic Calendar News

FHTX / Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. Read More

Demo Live Account See Partner Details

Content Topics

Foghorn

Therapeutics

Inc

FHTX

Surges

12 This

fhtx

12 8

Indication

Further

Gains

Stock

Posted: Jul 10 2023, 05:44

Author Name: Zacks Investment Research

FHTX News

By GlobeNewsWire
October 4, 2023

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a ne

By Seeking Alpha
August 16, 2023

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology

By Zacks Investment Research
August 4, 2023

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compar

By Zacks Investment Research
July 10, 2023

Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate r

By Zacks Investment Research
May 8, 2023

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compar

By Zacks Investment Research
April 27, 2023

Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?

Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate r

By Market Watch
April 24, 2023

Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial

Foghorn Therapeutics Inc.'s stock FHTX slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partia

By GlobeNewsWire
April 10, 2023

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023

CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a n

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.